KONINKLIJKE PHILIPS NV
For the period ended Oct 31, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Oct 31, 2025 · Filed Nov 4, 2025
Use the contents to explore the available documents and sections.
Contents
Outlook
Philips reiterates its confidence in delivering the full-year 2025 outlook:
Comparable sales growth: 1%-3%
Adjusted EBITA margin: 11.3%-11.8%, now expected toward the upper end of the range
Free cash flow: EUR 0.2-0.4 billion (including the payout in the first quarter of 2025 of EUR 1,025 million Philips Respironics recall-related medical monitoring and personal injury settlements in the US.)
This outlook excludes ongoing Philips Respironics-related proceedings, including the investigation by the US Department of Justice.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.